Cramer backs BillionToOne as diagnostics play amid AI caution

On the April 27 episode of Mad Money, financial commentator Jim Cramer recommended purchasing shares of BillionToOne, Inc. (NASDAQ:BLLN). During the show’s lightning round segment, Cramer characterised the firm as a "real company" and a "winner," highlighting its precision molecular diagnostics platform which counts DNA molecules to enhance disease detection, including non-invasive prenatal screening and liquid biopsies for cancer.

Cramer contrasted this potential with the underperformance of other diagnostic firms such as Becton, Dickinson, and Abbott Labs, which he noted had been performing poorly. He advised caution regarding other high-flying artificial intelligence stocks while expressing bullish sentiment on BillionToOne, noting that the stock had not previously surged despite the potential of its diagnostics platform.

The recommendation occurred during the "lightning round" segment of the show, where a caller sought Cramer’s opinion on the stock. Cramer commented: "We like BillionToOne. We looked at it, we thought the name was so silly… But it’s a real company… That’s going to be very good. I say buy it."

BillionToOne, Inc. develops precision molecular diagnostics using a platform that counts DNA molecules to improve disease detection. The company’s tests include non-invasive prenatal screening and liquid biopsies to detect and monitor cancer mutations. Cramer was bullish on the stock when a caller inquired about the stock during the April 27 episode, as he commented: "We looked into BillionToOne. We think it’s a really good diagnostic company. Now, the diagnostic companies themselves have been going down, whether it be Becton, Dickinson, whether it be Abbott Labs, they’ve not been working. That said, this stock never ran to begin with. I think BillionToOne’s a winner."

While the source article is published by Yahoo Finance and includes promotional content from Insider Monkey, which suggests alternative AI stock investments, the core event remains Cramer’s specific commentary on BillionToOne. The recommendation stands as a distinct call within the broader market backdrop of April 2026, where US stock markets rose during a summit between President Donald Trump and Chinese President Xi Jinping in Beijing.